<
 

Drug Information

View drug alerts Information in California, Georgia, or New York
 
The Drug Information Center has a wealth of information to help you understand how drugs impact your health as well as their place in today's healthcare environment. 
 
The information you'll find in the center covers a number of important topics ranging from drug safety and side effects to medication costs and errors. You'll also notice from time to time we will display drug alerts. These alerts will let you know when a New Drug is put on the market, if a drug has been recalled, and if a drug has a new indication or use. 
 
 
Drug Name Drug Reason Date
Vectibix
The Food and Drug Administration (FDA) approved Vectibix® (panitumumab injection) for individuals with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. Source: FDA website
New Indication 06-29-17
Orencia
The Food and Drug Administration (FDA) approved Orencia® (abatacept injection) for the treatment of active psoriatic arthritis (PsA) in adults. Source: FDA website
New Indication 07-06-17
Triptodur
The Food and Drug Administration (FDA) approved TriptodurTM (triptorelin injection) for the treatment of individuals 2 years of age and older with central precocious puberty (CPP). Dosing is once every 6 months. Source: FDA website
New Drug 06-30-17
Fibryna
The Food and Drug Administration (FDA) approved Fibryna® (fibrinogen, human, concentrate injection) for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Source: FDA website
New Drug 06-07-17
Endari
The Food and Drug Administration (FDA) approved EndariTM (L-glutamine oral powder) to reduce the acute complications of sickle cell disease in adult and pediatric individuals 5 years and older. Source: FDA website
New Drug 07-07-17
NovoPen Echo Insulin Delivery Device
Novo Nordisk announced a recall of insulin cartridge holders used in a small number of NovoPen Echo batches because they may crack or break if exposed to certain chemicals. Contact your healthcare provider with questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm565955.htm Source: FDA website
Drug Recall 07-06-17
Zykadia
The Food and Drug Administration (FDA) approved Zykadia® (ceritinib capsules) for use in first-line anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Source: FDA website
New Indication 05-26-17
Zerviate
The Food and Drug Administration (FDA) approved ZerviateTM (cetirizine ophthalmic solution) for the treatment of ocular itching associated with allergic conjunctivitis. Source: FDA website
New Drug 06-01-17
Isentress HD
The Food and Drug Administration (FDA) approved Isentress® HD (raltegravir tablets) for use in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and pediatric individuals (weighing 40 kg or more) who are treatment-naive or whose virus has been suppressed on an initial regimen of Isentress 400 mg twice daily. Source: FDA website
New Drug 05-30-17
Rebinyn
The Food and Drug Administration (FDA) approved Rebinyn® (nonacog beta pegol injection) for the treatment of individuals with hemophilia B. Source: FDA website
New Drug 06-01-17
Mibela 24 FE
Lupin Pharmaceuticals announced a recall of one lot of Mibela 24 FE (norethindrone acetate/ethinyl estradiol chewable tablets and ferrous fumarate tablets) due to out of sequence tablets and missing expiration date and lot information. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm560908.htm Source: FDA website
Drug Recall 05-29-17
Bavencio
The Food and Drug Administration (FDA) approved Bavencio® (avelumab injection) for individuals with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Source: FDA website
New Indication 05-09-17
Keytruda
The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab injection) in combination with pemetrexed and carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Source: FDA website
New Indication 05-10-17
Keytruda
The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab injection) for individuals with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Source: FDA website
New Indication 05-18-17
Keytruda
The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab injection) for individuals with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. Source: FDA website
New Indication 05-18-17
Kalydeco
The Food and Drug Administration (FDA) approved Kalydeco® (ivacaftor tablets and oral granules) for use in individuals with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Source: FDA website
New Indication 05-18-17
Minolira
The Food and Drug Administration (FDA) approved MinoliraTM (minocycline extended-release tablets) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in individuals aged 12 years and older. Source: FDA website
New Drug 05-10-17
Canagliflozin
The Food and Drug Administration (FDA) has concluded that the type 2 diabetes medication canagliflozin (Invokana®, Invokamet®, and Invokamet® XR) causes an increased risk of leg and foot amputations. New warnings, including a Boxed Warning, will be added to canagliflozin drug labels. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm558605.htm Source: FDA website
Drug Warning 05-16-17
Ilaris
TThe Food and Drug Administration (FDA) approved Ilaris® (canakinumab injection) for use in individuals with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF). Source: FDA website
New Indication 9/23/2016
Stelara
The Food and Drug Administration (FDA) approved Stelara® (ustekinumab injection) for the treatment of moderately to severely active Crohn’s disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.Source: FDA website
New Indication 9/26/2016
Orkambi
The Food and Drug Administration (FDA) approved Orkambi® (lumacaftor/ivacaftor tablets) for use in children with cystic fibrosis aged 6-11 years who have 2 copies of the F508del mutation. Source: FDA website
New Indication 9/28/2016
Epaned
The Food and Drug Administration (FDA) approved Epaned® (enalapril maleate oral solution) for the treatment of hypertension in adults and children >1 month, to lower blood pressure. It is also indicated to treat symptomatic heart failure and asymptomatic left ventricular dysfunction. Source: FDA website
New Drug 9/23/2016
Direct-Acting Antivirals for Hepatitis C
The Food and Drug Administration (FDA) is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any individual who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medications for hepatitis C virus. Contact your healthcare provider with any questions. More details may be found at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm Source: FDA website
Drug Warning 10/4/2016
Cosentyx
The Food and Drug Administration (FDA) approved Cosentyx® (secukinumab injection) for the treatment of adults with active ankylosing spondylitis (AS). Source: FDA website
New Indication 01-19-16
Arzerra
The Food and Drug Administration (FDA) approved Arzerra® (ofatumumab injection) for extended treatment of individuals who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Source: FDA website
New Indication 01-19-16
Kyprolis
The Food and Drug Administration (FDA) approved Kyprolis™ (carfilzomib injection) in combination with dexamethasone or lenalidomide plus dexamethasone for the treatment of individuals with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Source: FDA website
New Indication 01-21-16
Emverm
The Food and Drug Administration (FDA) approved Emverm™ (mebendazole chewable tablets) for treatment of pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), common roundworm (Ascaris lumbricoides), common hookworm (Ancylostoma duodenale), and American hookworm (Necator americanus), as single or mixed infections. Source: FDA website
New Drug 01-15-16
Humulin R U-500 KwikPen
The Food and Drug Administration (FDA) approved Humulin® R U-500 KwikPen® (human insulin pre-filled injection), a highly concentrated formulation of insulin providing insulin that is 5 times more concentrated than U-100 insulin products to treat high blood sugar in type 1 and 2 diabetes. Source: FDA website
New Drug 01-21-16
Abbott's Compounding Pharmacy
Abbott's Compounding Pharmacy announced a voluntary recall of all unexpired lots of sterile compounded products due to lack of sterility assurance. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm482102.htm Source: FDA website
Drug Recall 01-16-16
Cosentyx
The Food and Drug Administration (FDA) approved Cosentyx® (secukinumab injection) for the treatment of adults with active psoriatic arthritis (PsA). Source: FDA website
New Indication 01-19-16
Botox
The Food and Drug Administration (FDA) approved Botox® (onabotulinumtoxinA injection) for the treatment of lower limb spasticity in adults to decrease the severity of increased muscle stiffness in ankle and toe muscles. Source: FDA website
New Indication 01-22-16
Opdivo
The Food and Drug Administration (FDA) approved Opdivo® (nivolumab injection) in combination with Yervoy® (ipilimumab injection) for the treatment of individuals with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. Source: FDA website
New Indication 01-25-16
Halaven
The Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate injection) for the treatment of unresectable or metastatic liposarcoma in individuals who have received prior chemotherapy containing an anthracycline. Source: FDA website
New Indication 01-28-16
Emend
The Food and Drug Administration (FDA) approved Emend® (fosaprepitant dimeglumine injection) for use in combination with other antiemetic agents to prevent delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). Source: FDA website
New Indication 02-04-16
Dexilant SoluTab
The Food and Drug Administration (FDA) approved Dexilant™ SoluTab (dexlansoprazole delayed-release orally disintegrating tablets) for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in individuals 18 years and older. Source: FDA website
New Drug 01-27-16
Adzenys XR-ODT
The Food and Drug Administration (FDA) approved Adzenys XR-ODT™ (amphetamine extended-release orally disintegrating tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in individuals 6 years and older. Source: FDA website
New Drug 01-27-16
Onzetra Xsail
The Food and Drug Administration (FDA) approved Onzetra™ Xsail™ (sumatriptan nasal powder) for the treatment of migraine with or without aura in adults. Source: FDA website
New Drug 01-29-16
Zembrace SymTouch
The Food and Drug Administration (FDA) approved Zembrace™ SymTouch™ (sumatriptan succinate subcutaneous injection) for the treatment of acute migraine episodes with or without aura in adults who are inadequately managed with existing treatment regimens. Source: FDA website
New Drug 01-29-16
Zepatier
The Food and Drug Administration (FDA) approved Zepatier™ (elbasvir/grazoprevir tablets) for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections. Source: FDA website
New Drug 01-28-16
Daklinza
The Food and Drug Administration (FDA) approved Daklinza™ (daclatasvir tablets) for use in chronic hepatitis C virus (HCV) genotypes 1 and 3 with human immunodeficiency virus (HIV)-1 co-infection, advanced cirrhosis, and post-liver transplant recurrence of HCV. Source: FDA website
New Indication 02-05-16
Harvoni
The Food and Drug Administration (FDA) approved Harvoni® (ledipasvir/sofosbuvir tablets) in combination with ribavirin for 12 weeks for use in chronic hepatitis C virus (HCV) genotype 1- or 4- infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A) and for HCV genotype 1-infected individuals with decompensated cirrhosis (Child-Pugh B/C) including those who have undergone liver transplantation. Source: FDA website
New Indication 02-16-16
Ibrance
The Food and Drug Administration (FDA) approved Ibrance® (palbociclib capsules) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy. Source: FDA website
New Indication 02-19-16
Gazyva
The Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab injection) for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. Source: FDA website
New Indication 02-26-16
Afinitor
The Food and Drug Administration (FDA) approved Afinitor® (everolimus tablets) for the treatment of adults with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. Source: FDA website
New Indication 02-26-16
Sernivo
The Food and Drug Administration (FDA) approved Sernivo™ (betamethasone dipropionate topical spray) for the treatment of mild to moderate plaque psoriasis in individuals 18 years of age and older. Source: FDA website
New Drug 02-08-16
Xeljanz
The Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib citrate extended-release tablets) for once-daily treatment of moderate to severe rheumatoid arthritis (RA) in individuals who have had an inadequate response or intolerance to methotrexate (MTX). Source: FDA website
New Drug 02-24-16
Briviact
The Food and Drug Administration (FDA) approved Briviact® (brivaracetam oral solution and tablet and injection) as add-on therapy for the treatment of partial onset seizures in individuals 16 years of age and older. Source: FDA website
New Drug 02-19-16
Complera
The Food and Drug Administration (FDA) approved labeling for Complera® (emtricitabine/tenofovir disoproxil fumarate/rilpivirine tablets) to include expanded use in pediatric individuals aged 12 to less than 18 years old for the treatment of human immunodeficiency virus (HIV)-1 infection. Source: FDA website
New Indication 03-02-16
Faslodex
The Food and Drug Administration (FDA) approved Faslodex® (fulvestrant injection) to include use in combination with palbociclib for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer whose cancer has progressed after endocrine therapy. Source: FDA website
New Indication 03-02-16
Imbruvica
The Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib capsules) as a first-line treatment for individuals with chronic lymphocytic leukemia (CLL). Source: FDA website
New Indication 03-04-16
Xalkori
The Food and Drug Administration (FDA) approved Xalkori® (crizotinib capsules) for the treatment of metastatic non-small cell lung cancer (NSCLC) in individuals whose tumors are ROSI-1 positive. Source: FDA website
New Indication 03-11-16
Cetylev
The Food and Drug Administration (FDA) approved CetylevTM (acetylcysteine effervescent tablets for oral solution) as an antidote for acetaminophen overdose to prevent or lessen liver damage after the ingestion of a potentially hepatotoxic quantity of acetaminophen. Source: FDA website
New Drug 01-29-16
Idelvion
The Food and Drug Administration (FDA) approved Idelvion® (albutrepenonacog alfa injection) for the on-demand control and prevention of bleeding episodes, management of postoperative bleeding, and as prophylaxis to reduce the frequency of bleeding episodes in hemophilia B in children and adults. Source: FDA website
New Drug 03-04-16
Odefsey
The Food and Drug Administration (FDA) approved Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide tablets) for the treatment of human immunodeficiency virus (HIV)-1 infection. Source: FDA website
New Drug 03-01-16
Truvada
The Food and Drug Administration (FDA) approved Truvada® (emtricitabine/tenofovir disoproxil fumarate tablets) for pediatric individuals with human immunodeficiency virus (HIV)-1 weighing at least 17 kg. Source: FDA website
New Indication 03-14-16
Evomela
The Food and Drug Administration (FDA) approved Evomela™ (captisol-enabled melphalan injection) for the treatment of individuals with multiple myeloma. Specific labeling is for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant and palliative treatment for individuals for whom oral therapy is not appropriate. Captisol technology improves the stability of melphalan extending its use time to 5 hours, allowing for slower infusion rate, and for longer administration durations for pre-transplant chemotherapy. Source: FDA website
New Drug 03-14-16
Kovaltry
The Food and Drug Administration (FDA) approved Kovaltry® (antihemophilic factor VIII, recombinant injection) for the treatment of hemophilia A in adults and children. Source: FDA website
New Drug 03-17-16
Taltz
The Food and Drug Administration (FDA) approved Taltz® (ixekizumab injection) for the treatment of adults with moderate-to-severe plaque psoriasis. Source: FDA website
New Drug 03-22-16
Cinqair
The Food and Drug Administration (FDA) approved Cinqair® (reslizumab injection) for the maintenance treatment of severe asthma in individuals 18 years and older with an eosinophilic phenotype. Source: FDA website
New Drug 03-23-16
Eye drops
The Food and Drug Administration (FDA) is warning the public about eye drop bottles that have loose plastic safety seals or tamper evident rings below the bottle cap that may fall onto the eye when the product is used. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm490862.htm Source: FDA website
Drug Warning 03-15-16
Defitelio
The Food and Drug Administration (FDA) approved Defitelio® (defibrotide injection) for the treatment of adult and pediatric individuals with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). Source: FDA website
New Drug 03-03-16
Descovy
The Food and Drug Administration (FDA) approved Descovy® (emtricitabine/tenofovir alafenamide tablets) for the treatment of human immunodeficiency virus (HIV)-1 infection in patients 12 years of age and older, in combination with other antiretroviral agents. Source: FDA website
New Drug 04-04-16
Metformin-containing diabetes medications
The Food and Drug Administration (FDA) is requiring labeling changes regarding the recommendations for metformin-containing medications for diabetes to expand use in certain individuals with reduced kidney function. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm Source: FDA website
Drug Warning 04-08-16
Saxagliptin and alogliptin containing diabetes medications
The Food and Drug Administration (FDA) has found that type 2 diabetes medications containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in individuals who already have heart or kidney disease. The FDA is adding new warnings to the drug labels. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm Source: FDA website
Drug Warning 04-05-16
Bromsite
The Food and Drug Administration (FDA) approved BromSite™ (bromfenac ophthalmic solution) for the treatment of inflammation and prevention of pain in individuals undergoing cataract surgery. Source: FDA website
New Drug 04-08-16
Venclexta
The Food and Drug Administration (FDA) approved Venclexta™ (venetoclax tablets) for the treatment of individuals with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. Source: FDA website
New Drug 04-11-16
Gilotrif
The Food and Drug Administration (FDA) approved Gilotrif® (afatinib tablets) for the treatment of individuals with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy. Source: FDA website
New Indication 04-15-16
G4 Platinum and G5 Mobile Continuous Glucose Monitoring receivers
Dexcom announced a voluntary recall of its Continuous Glucose Monitoring systems due to possible audible alarm failure. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm495468.htm Source: FDA website
Drug Recall 04-11-16
Focus Diagnostics Laboratory examination kits
Focus Diagnostics announced a voluntary recall of Simplexa Herpes Simplex Virus 1 and 2 Direct and Simplexa Group A Strep Direct examination kits containing the Direct Amplification Discs due to poor lamination between the sample reaction wells. This could lead to inaccurate test results. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm496099.htm Source: FDA website
Drug Recall 04-14-16
Orfadin
The Food and Drug Administration (FDA) approved Orfadin® (nitisinone oral suspension) for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Source: FDA website
New Drug 04-26-16
Xtampza ER
The Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone extended-release capsules) for the treatment of chronic pain. Source: FDA website
New Drug 04-26-16
Bevespi Aerosphere
The Food and Drug Administration (FDA) approved Bevespi Aerosphere™ (glycopyrrolate/formoterol fumarate oral inhalation aerosol) for the long-term, maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease (COPD), including bronchitis and/or emphysema. Source: FDA website
New Drug 04-25-16
Cabometyx
The Food and Drug Administration (FDA) approved Cabometyx™ (cabozantinib tablets) for the treatment of advanced renal cell carcinoma in individuals who have received prior anti-angiogenic therapy. Source: FDA website
New Drug 04-25-16
ProAir RespiClick
The Food and Drug Administration (FDA) approved ProAir RespiClick (albuterol sulfate oral inhalation powder) for the treatment or prevention of bronchospasm in children aged 4 to 11 years with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB). Source: FDA website
New Indication 04-29-16
Viekira Pak
The Food and Drug Administration (FDA) approved Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) without ribavirin in individuals with genotype 1b chronic hepatitis C virus (HCV) infection and compensated cirrhosis. Source: FDA website
New Indication 04-25-16
Nuplazid
The Food and Drug Administration (FDA) approved Nuplazid™ (pimavanserin tablets) for the treatment of psychosis associated with Parkinson's disease. Source: FDA website
New Drug 04-29-16
Fycompa
The Food and Drug Administration (FDA) approved Fycompa® (perampanel oral suspension) for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in individuals with epilepsy 12 years and older. Source: FDA website
New Drug 05-02-16
Akovaz
The Food and Drug Administration (FDA) approved Akovaz™ (ephedrine sulfate injection) for the management of hypotension in surgical settings. Source: FDA website
New Drug 04-29-16
Ameluz
The Food and Drug Administration (FDA) approved Ameluz® (aminolevulinic acid gel) for use in combination with photodynamic therapy for the treatment of actinic keratoses on the face and scalp. Source: FDA website
New Drug 05-10-16
Brintellix
The Food and Drug Administration (FDA) approved a brand name change for the antidepressant Brintellix® (vortioxetine tablets) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the blood-thinning medication Brilinta® (ticagrelor tablets). The new brand name of the drug will be Trintellix®. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498607.htm Source: FDA website
Drug Warning 05-02-16
Aripiprazole
The Food and Drug Administration (FDA) is warning that impulse-control problems have been reported with the use of the antipsychotic drug aripiprazole. New warnings will be added to the drug labels for all aripiprazole-containing products. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm498823.htm Source: FDA website
Drug Warning 05-03-16
Olanzapine
The Food and Drug Administration (FDA) is warning that the antipsychotic drug olanzapine can cause a rare but serious skin reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). New warnings will be added to the drug labels for all olanzapine-containing products. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500123.htm Source: FDA website
Drug Warning 05-10-16
Fluoroquinolones
The Food and Drug Administration (FDA) is advising that the serious side effects associated with fluoroquinolone antibacterials generally outweigh the benefits for individuals with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For individuals with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500665.htm Source: FDA website
Drug Warning 05-12-16
Lenvima
The Food and Drug Administration (FDA) approved Lenvima® (lenvatinib capsules) in combination with everolimus for the treatment of individuals with advanced renal cell carcinoma who were previously treated with an anti-angiogenic therapy. Source: FDA website
New Indication 05-13-16
Opdivo
The Food and Drug Administration (FDA) approved Opdivo® (nivolumab injection) for the treatment of individuals with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation Adcetris® (brentuximab vedotin injection). Source: FDA website
New Indication 05-17-16
Tecentriq
The Food and Drug Administration (FDA) approved Tecentriq™ (atezolizumab injection) for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery. Source: FDA website
New Drug 05-18-16
Nizoral
The Food and Drug Administration (FDA) is warning healthcare professionals to avoid prescribing the antifungal medication ketoconazole oral tablets for the unapproved uses of treating skin and nail fungal infections. Use of this medication carries the risk of serious liver damage, adrenal gland problems, and harmful drug interactions. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm Source: FDA website
Drug Warning 05-19-16
Canagliflozin
The Food and Drug Administration (FDA) is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations in individuals treated with the diabetes medicine canagliflozin (Invokana®, Invokamet®). The agency will update the public when there is more information. Contact your healthcare professional with any questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm501565.htm Source: FDA website
Drug Warning 05-18-16
Invokamet
The Food and Drug Administration (FDA) approved Invokamet® (canagliflozin/metformin tablets) as a first-line treatment for adults with type 2 diabetes. Source: FDA website
New Indication 05-18-16
Fanapt
The Food and Drug Administration (FDA) approved Fanapt® (iloperidone tablets) as a maintenance treatment for adults with schizophrenia. Source: FDA website
New Indication 05-18-16
Teflaro
The Food and Drug Administration (FDA) approved Teflaro® (ceftaroline fosamil injection) in individuals aged 2 months to less than 18 years old with acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), and community-acquired bacterial pneumonia (CABP) caused by Streptococcal pneumoniae and other designated susceptible bacteria.
New Indication 05-18-16
Crestor
The Food and Drug Administration (FDA) approved Crestor® (rosuvastatin tablets) for use in pediatric patients aged 7–17 years with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total C, nonHDL-C, and ApoB as adjunct to diet, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).
New Indication 05-18-16
Flucelvax Quadrivalent
The Food and Drug Administration (FDA) approved Flucelvax Quadrivalent® (four-strain influenza vaccine injection) for influenza virus infection prevention in individuals 4 years of age and older. Source: FDA website
New Drug 05-18-16
Probuphine
The Food and Drug Administration (FDA) approved Probuphine® (buprenorphine implant for subdermal administration) for the maintenance treatment of opioid dependence. Source: FDA website
New Drug 05-18-16
Ocaliva
The Food and Drug Administration (FDA) approved Ocaliva™ (obeticholic acid tablets) for the treatment of primary biliary cholangitis. Source: FDA website
New Drug 05-18-16
Afstyla
The Food and Drug Administration (FDA) approved Afstyla® (antihemophilic factor, recombinant, single chain injection) for the treatment of adults and children with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes. Source: FDA website
New Drug 05-18-16
Jentadueto XR
The Food and Drug Administration (FDA) approved Jentadueto® XR (linagliptin/metformin tablets) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin are appropriate. Source: FDA website
New Drug 05-18-16
Zinbryta
The Food and Drug Administration (FDA) approved Zinbryta™ (daclizumab injection) for the treatment of relapsing forms of multiple sclerosis (MS). Source: FDA website
New Drug 05-18-16
Byvalson
The Food and Drug Administration (FDA) approved Byvalson™ (nebivolol/valsartan tablets) for the treatment of hypertension to lower blood pressure. Source: FDA website
New Drug 06-06-16
Jetrea
The Food and Drug Administration (FDA) approved Jetrea® (ocriplasmin intravitreal injection) in an "already diluted" formulation for the treatment of symptomatic vitreomacular adhesion. Source: FDA website
New Drug 06-08-16
Loperamide
The Food and Drug Administration (FDA) is warning that taking higher than recommended doses of over-the-counter (OTC) and prescription diarrhea medicine loperamide, including through abuse or misuse of the product, can cause serious heart problems that can lead to death. Contact your healthcare professional with questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm Source: FDA website
Drug Warning 06-07-16
Nature Made
Pharmavite announced a voluntary recall on specific lots of Nature Made products due to possible Salmonella or Staphylococcus aureus contamination. Contact your healthcare professional with questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505761.htm Source: FDA website
Drug Warning 06-08-16
Over-the-Counter Antacid Products Containing Aspirin
The Food and Drug Administration (FDA) is warning consumers about the risk of serious bleeding when using over-the-counter (OTC) aspiring-containing antacids to treat heartburn, sour stomach, acid indigestion, or upset stomach. Contact your healthcare professional with questions. Details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505190.htm Source: FDA website
Drug Warning 06-06-16
Vaxchora
The Food and Drug Administration (FDA) approved Vaxchora™ (oral cholera vaccine) for the prevention of cholera caused by serogroup 01 for use in adults aged 18 through 64 years traveling to cholera-affected regions. Source: FDA website
New Drug 06-10-16
GoNitro
The Food and Drug Administration (FDA) approved GoNitro™ (nitroglycerin powder for sublingual use) to prevent angina pectoris. Source: FDA website
New Drug 06-13-16
Lansoprazole ODT
The Food and Drug Administration (FDA) approved Lansoprazole orally disintegrating tablets for the treatment of peptic ulcer. A trade name has not yet been determined. Source: FDA website
New Drug 06-07-16
Rayaldee
The Food and Drug Administration (FDA) approved Rayaldee® (calcifediol extended-release capsules) for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels <30 ng/mL. Source: FDA website
New Drug 06-17-16
Canagliflozin and Dapagliflozin
The Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin and dapagliflozin. Contact your healthcare professional with any questions. More details may be found at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm Source: FDA website <30 ng/mL. Source: FDA website
Drug Warning 06-14-16
Humira
The Food and Drug Administration (FDA) approved Humira® (adalimumab injection) for the treatment of non-infectious intermediate, posterior, and panuveitis. Source: FDA website
New Indication 07-01-16
Xolair
The Food and Drug Administration (FDA) approved Xolair® (omalizumab injection) for an expanded age range to include children aged 6-11 years with moderate to severe persistent asthma with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids. Source: FDA website
New Indication 07-08-16
Prevnar
The Food and Drug Administration (FDA) approved Prevnar 13® (pneumococcal 13-valent conjugate vaccine injection) for an expanded age range to include adults 18 through 49 years of age for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae serotypes. Source: FDA website
New Indication 07-12-16
Dexilant and Dexilant SoluTab
The Food and Drug Administration (FDA) approved Dexilant® (dexlansoprazole delayed-release capsules and Dexilant® SoluTab (dexlansoprazole delayed-release orally-disintegrating tablets) for the treatment of gastroesophageal reflux disease (GERD) in individuals aged 12 to 17 years. Source: FDA website
New Indication 07-13-16
Syndros
The Food and Drug Administration (FDA) approved Syndros™ (dronabinol oral solution) for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in individuals who have failed to respond adequately to conventional antiemetic treatments. Source: FDA website
New Drug 07-05-16
Xiidra
The Food and Drug Administration (FDA) approved Xiidra™ (lifitegrast ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease. Source: FDA website
New Drug 07-12-16
Epclusa
The Food and Drug Administration (FDA) approved Epclusa® (sofosbuvir/velpatasvir tablets) for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Source: FDA website
New Drug 06-28-16
Prezista
The Food and Drug Administration (FDA) approved Prezista® (darunavir tablets) for expanded use in pregnant women with human immunodeficiency virus (HV) infection. Source: FDA website
New Indication 07-18-16
Berinert
The Food and Drug Administration (FDA) approved Berinert® (C1 esterase inhibitor injection) for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in individuals < 12 years old. Source: FDA website
New Indication 07-18-16
Namzaric
The Food and Drug Administration (FDA) approved Namzaric™ (memantine/donepezil extended-release capsules) for expanded use allowing individuals with moderate to severe Alzheimer’s disease who are currently stabilized on donepezil 10 mg to start directly with Namzaric. New dosage strengths were also approved: 7 mg/10 mg and 21 mg/10 mg capsules. Source: FDA website
New Indication 07-19-16
Synjardy
The Food and Drug Administration (FDA) approved Synjardy® (empagliflozin/metformin tablets) for expanded use to include treatment naïve adults with type 2 diabetes. Source: FDA website
New Indication 07-19-16
Belviq XR
The Food and Drug Administration (FDA) approved Belviq XR® (lorcaserin extended-release tablets) for use with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of ≥30 kg/m2 (obese) or BMI of ≥27 kg/m2 (overweight) with at least one weight-related medical condition (e.g., high blood pressure, high cholesterol, type 2 diabetes). Source: FDA website
New Drug 07-19-16
Relistor
The Food and Drug Administration (FDA) approved Relistor® (methylnaltrexone bromide tablets) for the treatment of opioid-induced constipation for individuals with pain not caused by cancer. Source: FDA website
New Drug 07-19-16
Viekira XR
The Food and Drug Administration (FDA) approved Viekira XR® (dasabuvir/ombitasvir/paritaprevir and ritonavir extended-release tablets) for the once daily treatment of adults with chronic hepatitis C virus (HCV) genotype 1 infection. Source: FDA website
New Drug 07-22-16
Adlyxin
The Food and Drug Administration (FDA) approved Adlyxin™ (lixisenatide injection) for the once-daily treatment of adults with type 2 diabetes mellitus. Source: FDA website
New Drug 07-27-16
Human chorionic gonadotropin (HCG) and sermorelin
Talon Compounding Pharmacy (TCP) announced a voluntary recall of all unexpired lots of lyophilized HCG and sermorelin aseptically compounded and packaged by TCP due to a lack of sterility assurance. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm512729.htm Source: FDA website
Drug Recall 07-22-16
Fluoroquinolones
The Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (oral or injectable) with regards to disabling and potentially permanent adverse effects affecting the tendons, muscles, joints, nerves, and central nervous system. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm513065.htm Source: FDA website
Drug Warning 07-26-16
Qbrelis
The Food and Drug Administration (FDA) approved Qbrelis™ (lisinopril oral solution) for the treatment of hypertension in adults and pediatric individuals 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults. Source: FDA website
New Drug 07-29-16
Sustol
The Food and Drug Administration (FDA) approved Sustol® (granisetron extended-release injection) for use with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Source: FDA website
New Drug 08-10-16
Dysport
The Food and Drug Administration (FDA) approved Dysport® (abobotulinumtoxinA injection) for the treatment of lower limb spasticity in individuals age 2 years and older. Source: FDA website
New Indication 08-01-16
Keytruda
The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab injection) for the treatment of individuals with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Source: FDA website
New Indication 08-05-16
PharmaTech liquid drug and dietary supplement products
PharmaTech announced a voluntary recall of all their liquid products due to a potential risk of product contamination with Burkholderia cepacia. Contact your healthcare professional with any questions. More details including affected products may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm515625.htm Source: FDA website
Drug Recall 08-09-16
Arzerra
The Food and Drug Administration (FDA) approved Arzerra®(ofatumumab injection) for use in combination with fludarabine and cyclophosphamide for the treatment of individuals with relapsed chronic lymphocytic leukemia (CLL). Source: FDA website
New Indication 08-31-16
Troxyca ER
The Food and Drug Administration (FDA) approved Troxyca® ER (naltrexone/oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Source: FDA website
New Drug 08-19-16
Eye/wash/Eye irrigating solutions
United Exchange Corp. of Cerritos, CA announced a voluntary recall of Rugby-branded Eye Irrigating Solution and Major-branded Eye Wash due to microbial contamination. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519570.htm Source: FDA website
Drug Recall 09-07-16
GlucaGen HypoKit (glucagon rDNA origin)
Novo Nordisk announced a voluntary recall of six batches of GlucaGen HypoKit due to customer complaints of detached needles on the syringe. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519907.htm Source: FDA website
Drug Recall 09-09-16
Lamotrigine
Impax Laboratories announced a voluntary recall of one lot of Lamotrigine orally disintegrating tablets 20 mg due to incorrect labeling of blister cards. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518486.htm Source: FDA website
Drug Recall 08-29-16
Opioid pain or cough medicines combined with benzodiazepines
The Food and Drug Administration (FDA) is requiring the addition of Boxed Warnings to the drug labeling of prescription opioid pain and prescription opioid cough medicine and benzodiazepines regarding serious risks of these medications. Contact your healthcare professional with any questions. More details may be viewed at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm518710.htm Source: FDA website
Drug Warning 08-31-16
Cuvitru
The Food and Drug Administration (FDA) approved Cuvitru® (immune globulin, human 20% subcutaneous injection) for the treatment of primary immunodeficiency disorders in individuals 2 years and older. Source: FDA website
New Drug 09-14-16
Yosprala
The Food and Drug Administration (FDA) approved Yosprala™ (omeprazole/aspirin tablets) to treat individuals who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers. Source: FDA website
New Drug 09-15-16
Kyleena
The Food and Drug Administration (FDA) approved Kyleena™ (levonorgestrel-releasing intrauterine system) for the prevention of pregnancy for up to 5 years. Source: FDA website
New Drug 09-19-16
Lomaira
The Food and Drug Administration (FDA) approved Lomaira™ (phentermine tablets) as a short-term (few weeks) adjunct in a regimen for weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in individuals with an initial body mass index > 30 kg/m2, or > 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Source: FDA website
New Drug 09-19-16
Invokamet XR
The Food and Drug Administration (FDA) approved Invokamet® XR (canagliflozin/metformin extended-release tablets) for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes when treatment with the two medications is appropriate. Source: FDA website
New Drug 09-21-16
Exondys 51
The Food and Drug Administration (FDA) approved Exondys 51™ (eteplirsen injection) for the treatment of Duchenne muscular dystrophy (DMD) in individuals with confirmed mutation of the DMD gene amenable to exon 51 skipping. Source: FDA website
New Drug 09-19-16
Wells Pharmacy Network
Wells Pharmacy Network announced a voluntary recall of all unexpired sterile products prepared between February 22, 2016 and September 14, 2016 due to concern over lack of sterility assurance. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm522103.htm Source: FDA website
Drug Recall 09-22-16
Hyoscyamine sulfate
Virtus Pharmaceuticals announced a voluntary recall of seven lots of Hyoscyamine sulfate 0.125 mg tablets, sublingual tablets, and orally disintegrating tablets due to superpotent and subpotent test results. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm520868.htm Source: FDA website
Drug Recall 09-15-16
Opdivo
The Food and Drug Administration (FDA) approved Opdivo® (nivolumab injection) for the treatment of individuals with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy. Source: FDA website
New Indication 11-10-16
Vemlidy
The Food and Drug Administration (FDA) approved Vemlidy® (tenofovir alafenamide tablets) for the treatment of adults with hepatitis B virus (HBV) infection with compensated liver disease. Source: FDA website
New Drug 11-11-16
Bonjesta
The Food and Drug Administration (FDA) approved Bonjesta (doxylamine succinate/pyridoxine HCL extended-release tablets) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Source: FDA website
New Drug 11-11-16
Intrarosa
The Food and Drug Administration (FDA) approved Intrarosa™ (prasterone vaginal insert) for the treatment of women experiencing moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. Source: FDA website
New Drug 11-17-16
Essure Permanent Birth Control System
Essure labeling now includes the addition of a boxed warning regarding adverse outcomes and the potential need for removal. The labeling will also include a Patient Decision Checklist. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm529241.htm Source: FDA website
Drug Warning 11-15-16
Xultophy
The Food and Drug Administration (FDA) approved Xultophy® (insulin degludec/liraglutide injection) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily. Source: FDA website
New Drug 11-21-16
Soliqua
The Food and Drug Administration (FDA) approved SoliquaTM (insulin glargine/lixisenatide injection for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide. Source: FDA website
New Drug 11-21-16
Darzalex
The Food and Drug Administration (FDA) approved Darzalex® (daratumumab injection) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for relapsed or refractory multiple myeloma. Source: FDA website
New Indication 11-21-16
Jardiance
The Food and Drug Administration (FDA) approved Jardiance® (empagliflozin tablets) to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease. Source: FDA website
New Indication 12-02-16
Belladonna Extract
Raritan Pharmaceuticals announced a voluntary recall of homeopathic products containing belladonna extract due to the potential for variation in the content of belladonna. Consult your healthcare provider with questions. More details including products affected may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm530642.htm Source: FDA website
Drug Recall 11-25-16
Avastin
The Food and Drug Administration (FDA) approved Avastin® (bevacizumab injection) for individuals with platinum-sensitive recurrent ovarian cancer in combination with chemotherapy. Source: FDA website
New Indication 12-06-16
Tresiba
The Food and Drug Administration (FDA) approved Tresiba® (insulin degludec injection) for expanded use to improve glycemic control in children and adolescents with both type 1 and type 2 diabetes. Source: FDA website
New Indication 12-19-16
Synjardy XR
The Food and Drug Administration (FDA) approved Synjardy® XR (empagliflozin/metformin extended-release tablets) as an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken. Source: FDA website
New Drug 12-13-16
Eucrisa
The Food and Drug Administration (FDA) approved Eucrisa™ (crisaborole ointment) for the treatment of mild to moderate atopic dermatitis in individuals aged 2 years or older. Source: FDA website
New Drug 12-14-16
Rubraca
The Food and Drug Administration (FDA) approved Rubraca™ (rucaparib tablets) for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test. Source: FDA website
New Drug 12-19-16
General anesthetic and sedation drugs
The Food and Drug Administration (FDA) is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect development of children’s brains. The FDA is requiring warnings to be added to labels of general anesthetic and sedation drugs. Contact your healthcare provider with any questions. More details may be viewed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm533195.htm Source: FDA website
Drug Warning 12-14-16
Adynovate
The Food and Drug Administration (FDA) approved Adynovate® (antihemophilic factor, recombinant, PEGylated injection) to treat hemophilia A in pediatric individuals 12 years and younger and for use in surgical settings for both pediatric and adult individuals. Source: FDA website
New Indication 12-27-16
Lucentis
The Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) for the treatment of individuals with myopic choroidal neovascularization (mCNV). Source: FDA website
New Indication 01-06-17
Arymo ER
The Food and Drug Administration (FDA) approved Arymo ™ ER (morphine sulfate extended-release tablets) for pain severe enough to require daily, around-the-clock, long-acting treatment for which other options are inadequate. Source: FDA website
New Drug 01-09-17
Spinraza
The Food and Drug Administration (FDA) approved Spinraza™ (nusinersen intrathecal injection) for the treatment of children and adults with spinal muscular atrophy (SMA). Source: FDA website
New Drug 12-23-16
Saphris
The Food and Drug Administration (FDA) approved Saphris® (asenapine tablets) for use as maintenance monotherapy treatment in adults with bipolar disorder. Source: FDA website
New Indication 01-18-17
Imbruvica
The Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib capsules) for the treatment of individuals with marginal zone lymphoma (MZL) who require systemic therapy and have received one or more prior anti-CD20-based therapy. Source: FDA website
New Indication 01-19-17
Vantrela ER
The Food and Drug Administration (FDA) approved Vantrela™ ER (hydrocodone bitartrate extended-release tablets) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Source: FDA website
New Drug 01-18-17
Rhofade
The Food and Drug Administration (FDA) approved Rhofade™ (oxymetazoline topical cream) for the treatment of persistent facial erythema associated with rosacea in adults. Source: FDA website
New Drug 01-19-17
Trulance
The Food and Drug Administration (FDA) approved Trulance™ (plecanatide tablets) for the treatment of chronic idiopathic constipation (CIC) in adults. Source: FDA website
New Drug 01-19-17
Latuda
The Food and Drug Administration (FDA) approved Latuda® (lurasidone tablets) for the treatment of schizophrenia in adolescents aged 13-17 years. Source: FDA website
New Indication 01-30-17
Symbicort
The Food and Drug Administration (FDA) approved Symbicort® (budesonide/formoterol fumarate dihydrate oral inhalation) for the treatment of asthma in pediatric individuals aged 6 to 12 years. Source: FDA website
New Indication 01-30-17
Stribild
The Food and Drug Administration (FDA) approved Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate tablets) for human immunodeficiency virus (HIV)-1 infection in pediatric individuals 12 years and older and weighing 35 kg or more. Source: FDA website
New Indication 01-31-17
Ofirmev
The Food and Drug Administration (FDA) approved Ofirmev® (acetaminophen injection) to include recommended dosing for treatment of fever in neonates (including premature neonates born 32 or more weeks gestational age) up to 28 days chronological age and for infants aged 29 days to 2 years. Source: FDA website
New Indication 02-01-17
Opdivo
The Food and Drug Administration (FDA) approved Opdivo® (nivolumab injection) for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy. Source: FDA website
New Indication 02-02-17
AirDuo RespiClick
The Food and Drug Administration (FDA) approved AirDuo™ RespiClick® (fluticasone propionate/salmeterol oral inhalation powder) for the treatment of asthma in individuals 12 years and older. Source: FDA website
New Drug 03-30-17
ArmonAir RespiClick
The Food and Drug Administration (FDA) approved ArmonAir™ RespiClick® (fluticasone propionate oral inhalation powder) as maintenance treatment of asthma as prophylactic therapy in individuals 12 years and older. Source: FDA website
New Drug 03-30-17
Chlorhexidine gluconate
The Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with skin antiseptic products containing chlorhexidine gluconate. Contact your healthcare provider with any questions. More details may be found at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm539575.htm Source: FDA website
Drug Warning 02-02-17
Revlimid
The Food and Drug Administration (FDA) approved Revlimid® (lenalidomide capsules) as maintenance treatment for individuals with multiple myeloma following autologous hematopoietic stem cell transplant (Auto-HSCT). Source: FDA website
New Indication 02-22-17
Technivie
The Food and Drug Administration (FDA) approved Technivie™ (ombitasvir/paritaprevir/ritonavir tablets) for individuals with genotype 4 chronic hepatitis C infection (HCV) with compensated cirrhosis. Source: FDA website
New Indication 02-27-17
Qtern
The Food and Drug Administration (FDA) approved Qtern® (dapagliflozin/saxagliptin tablets) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who have inadequate control with dapagliflozin 10 mg or who are already treated with dapagliflozin and saxagliptin. Source: FDA website
New Drug 02-28-17
Xermelo
The Food and Drug Administration (FDA) approved Xermelo™ (telotristat ethyl tablets) for the treatment of carcinoid syndrome diarrhea in combination with a somatostatin analog when symptoms are not adequately controlled with a somatostatin analog alone. Source: FDA website
New Drug 02-28-17
Odactra
The Food and Drug Administration (FDA) approved Odactra (house dust mite allergen extract sublingual tablets) for the treatment of house dust mite-induced allergic rhinitis in adults. Source: FDA website
New Drug 03-01-17
Edex
Endo Pharmaceuticals announced a recall of one lot of Edex® (alprostadil 10 mcg for injection) due to the potential lack of sterility assurance. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm543526.htm Source: FDA website
Drug Recall 02-27-17
Keytruda
The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab injection) for children and adults who have classical Hodgkin lymphoma (cHL) that has resisted treatment or relapsed after three or more prior lines of therapy. Source: FDA website
New Indication 03-14-17
Noctiva
The Food and Drug Administration (FDA) approved Noctiva™ (desmopressin acetate nasal spray) for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least twice per night to void. Source: FDA website
New Drug 03-03-17
Nipride RTU
The Food and Drug Administration (FDA) approved Nipride RTU (sodium nitroprusside ready to use injection) for the immediate reduction of blood pressure. It is also approved for producing controlled hypotension to reduce bleeding during surgery and for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure peripheral vascular resistance and mean arterial blood pressure. Source: FDA website
New Drug 03-08-17
Symproic
The Food and Drug Administration (FDA) approved Symproic® (naldemedine tablets) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Source: FDA website
New Drug 03-23-17
Kisqali
The Food and Drug Administration (FDA) approved Kisqali® (ribociclib tablets) as initial endocrine-based treatment of postmenopausal women with HR+/HER2− advanced or metastatic breast cancer used with an aromatase inhibitor. Source: FDA website
New Drug 03-13-17
Xadago
The Food and Drug Administration (FDA) approved Xadago® (safinamide tablets) for the treatment of Parkinson's disease as add-on therapy to levodopa/carbidopa. Source: FDA website
New Drug 03-21-17
Bavencio
The Food and Drug Administration (FDA) approved Bavencio® (avelumab injection) for treatment of adult and pediatric individuals 12 years and older with metastatic Merkel cell carcinoma (MCC). Source: FDA website
New Drug 03-23-17
Viberzi
The Food and Drug Administration (FDA) is warning that Viberzi® (eluxadoline tablets), a medication used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in individuals who do not have a gallbladder due to an increased risk of developing serious pancreatitis. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm546771.htm Source: FDA website
Drug Warning 03-15-17
Qudexy XR
The Food and Drug Administration (FDA) approved Qudexy® XR (topiramate extended-release capsules) for use as prophylaxis of migraine headaches in adults and children aged 12 years and older. Source: FDA website
New Indication 03-30-17
Humira
The Food and Drug Administration (FDA) approved Humira® (adalimumab injection) labeling to include the addition of moderate to severe fingernail psoriasis data for individuals with moderate to severe chronic plaque psoriasis. Source: FDA website
New Indication 03-30-17
Dupixent
The Food and Drug Administration (FDA) approved Dupixent® (dupilumab injection) for the treatment of adults with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Source: FDA website
New Drug 03-28-17
Ocrevus
The Food and Drug Administration (FDA) approved Ocrevus™ (ocrelizumab injection) for the treatment of individuals with relapsing or primary progressive forms of multiple sclerosis. Source: FDA website
New Drug 03-28-17
Zejula
The Food and Drug Administration (FDA) approved Zejula™ (niraparib capsules) for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Source: FDA website
New Drug 03-27-17
Ibrance
The Food and Drug Administration (FDA) approved Ibrance® (palbociclib capsules) for use with any aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Source: FDA website
New Indication 03-31-17
Austedo
The Food and Drug Administration (FDA) approved Austedo™ (deutetrabenazine tablets) for the treatment of chorea associated with Huntington's disease (HD). Source: FDA website
New Drug 04-03-17
EpiPen/EpiPen Jr
Mylan announced a voluntary recall of select lots of EpiPen® and EpiPen Jr® (epinephrine auto-injector) due to failure of device to activate. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm550165.htm Source: FDA website
Drug Recall 03-31-17
Trokendi XR
The Food and Drug Administration (FDA) approved Trokendi XR® (topiramate extended-release capsules) for prophylaxis of migraine headache in individuals 12 years of age and older. Source: FDA website
New Indication 04-06-17
Sovaldi
The Food and Drug Administration (FDA) approved Sovaldi® (sofosbuvir tablets) to treat hepatitis C virus (HCV) in children ages 12 to 17. Source: FDA website
New Indication 04-07-17
Harvoni
The Food and Drug Administration (FDA) approved Harvoni® (ledipasvir/sofosbuvir tablets) to treat hepatitis C virus (HCV) in children ages 12 to 17. Source: FDA website
New Indication 04-07-17
Tecentriq
The Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab injection) for the treatment of individuals with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. Source: FDA website
New Indication 04-17-17
Lucentis
The Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) to treat diabetic retinopathy in individuals with or without diabetic macular edema (DME). Source: FDA website
New Indication 04-17-17
Ingrezza
The Food and Drug Administration (FDA) approved Ingrezza™ (valbenazine capsules) for the treatment of tardive dyskinesia in adults. Source: FDA website
New Drug 04-17-17
Homeopathic teething products
The Food and Drug Administration (FDA) announced a voluntary recall of all lots of Hyland’s Baby and Hyland’s Baby Nighttime teething tablets made by Standard Homeopathic Company due to confirmed levels of belladonna. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm538687.htm Source: FDA website
Drug Recall 04-14-17
Phenobarbital
C.O. Truxton announced a voluntary recall of one lot of Phenobarbital 15 mg tablets due to a labeling error on declared strength. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554358.htm Source: FDA website
Drug Recall 04-21-17
Isomeric Pharmacy Solutions
Isomeric Pharmacy Solutions announced a voluntary recall of all lots of unexpired sterile products due to concerns of a lack of sterility assurance. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm551299.htm Source: FDA website
Drug Recall 04-06-17
Thymoglobulin
The Food and Drug Administration (FDA) approved Thymoglobulin® (anti-thymocyte globulin, [rabbit] injection) for use with concomitant immunosuppression in the prophylaxis of acute rejection in individuals receiving a kidney transplant. Source: FDA website
New Indication 04-24-17
Stivarga
The Food and Drug Administration (FDA) approved Stivarga® (regorafenib tablets) for the treatment of individuals with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Source: FDA website
New Indication 04-27-17
Xatmep
The Food and Drug Administration (FDA) approved Xatmep™ (methotrexate oral solution) for the treatment of acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric individuals. Source: FDA website
New Drug 04-26-17
RoxyBond
The Food and Drug Administration (FDA) approved RoxyBond™ (oxycodone tablets) for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Source: FDA website
New Drug 04-26-17
Brineura
The Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa injection for intraventricular use) as a treatment to slow loss of ability to walk or crawl in symptomatic pediatric individuals 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Source: FDA website
New Drug 04-27-17
Rydapt
The Food and Drug Administration (FDA) approved Rydapt® (midostaurin capsules) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are FMLT3 mutation-positive (FLT3+) as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Source: FDA website
New Drug 04-28-17
Illegal cancer treatments
The Food and Drug Administration (FDA) issued warning letters addressed to 14 U.S. based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat, or cure cancer. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554777.htm Source: FDA website
Drug Warning 04-25-17
Bunavail
The Food and Drug Administration (FDA) approved Bunavail® (buprenorphine/naloxone buccal film) for the induction of opioid addiction treatment. Source: FDA website
New Indication 05-02-17
Alunbrig
The Food and Drug Administration (FDA) approved Alunbrig™ (brigatinib tablets) for the treatment of individuals with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Source: FDA website
New Drug 04-28-17
Tymlos
The Food and Drug Administration (FDA) approved Tymlos™ (abaloparatide subcutaneous injection) for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or individuals who have failed or are intolerant to other available osteoporosis therapy. Source: FDA website
New Drug 04-28-17
Imfinzi
The Food and Drug Administration (FDA) approved Imfinzi™ (durvalumab injection) for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who have disease progression during or followng platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Source: FDA website
New Drug 05-01-17
Radicava
The Food and Drug Administration (FDA) approved Radicava™ (edaravone injection) to treat individuals with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease. Source: FDA website
New Drug 05-05-17
Dysport
The Food and Drug Administration (FDA) approved Dysport® (abobotulinumtoxinA injection) for the treatment of lower limb spasticity in adults. Source: FDA website
New Indication 06-16-17
Norvir
The Food and Drug Administration (FDA) approved Norvir® (ritonavir oral powder) for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection in children and adults. Source: FDA website
New Drug 06-08-17
Symjepi
The Food and Drug Administration (FDA) approved Symjepi™ (epinephrine injection) for the emergency treatment of allergic reactions including anaphylaxis. Source: FDA website
New Drug 06-15-17
Topical products by Phillips Company
Phillips Company announced a voluntary recall of all lots of Tetrastem, Diabecline, Tetracycline-ABC, VenomX, Acneen, StaphWash, StringMed, NoPain and LidoMed due to concerns of manufacturing practices. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563204.htm Source: FDA website
Drug Recall 06-14-17
Paliperidone extended-release
Teva Pharmaceuticals announced a voluntary recall of one lot of paliperidone extended-release tablets 3 mg due to dissolution test failure. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563358.htm Source: FDA website
Drug Recall 06-15-17
Eliquis
Bristol-Myers Squibb announced a voluntary recall of one lot of Eliquis 5 mg tablets due to customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. Contact your healthcare provider with any questions. More details may be viewed at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563035.htm Source: FDA website
Drug Recall 06-13-17
Mekinist and Tafinlar
The Food and Drug Administration (FDA) approved Mekinist® (trametinib tablets) and Tafinlar® (dabrafenib capsules) in combination for individuals with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by a Food and Drug Administration (FDA)-approved test. Source: FDA website
New Indication 06-22-17
Darzalex
The Food and Drug Administration (FDA) approved Darzalex® (daratumumab injection) in combination with pomalidomide and dexamethasone for the treatment of individuals with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Source: FDA website
New Indication 06-16-17
Cotempla XR-ODT
The Food and Drug Administration (FDA) approved Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) for the once-daily treatment of children 6-17 years of age with attention-deficit/hyperactivity disorder (ADHD). Source: FDA website
New Drug 06-20-17
Mydayis
The Food and Drug Administration (FDA) approved Mydayis™ (amphetamine mixed salts capsules) as once-daily treatment for ADHD in individuals 13 years of age and older. Source: FDA website
New Drug 06-20-17
Rituxan Hycela
The Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab/hyaluronidase injection) for adults with follicular lymphoma, diffuse B-cell lymphoma, and chronic lymphocytic leukemia. Source: FDA website
New Drug 06-22-17
Haegarda
The Food and Drug Administration (FDA) approved Haegarda® (C1 esterase inhibitor subcutaneous injection) for the prevention of hereditary angioedema (HAE) attacks in adolescents and adults. Source: FDA website
New Drug 06-22-17
Baxdela
The Food and Drug Administration (FDA) approved Baxdela™ (delafloxacin tablets and injection for intravenous use) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. Source: FDA website
New Drug 06-19-17
Bevyxxa
The Food and Drug Administration (FDA) approved Bevyxxa™ (betrixaban capsules) for the prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Source: FDA website
New Drug 06-23-17
Blincyto
The Food and Drug Administration (FDA) approved Blinctyo® (blinatumomab injection) for the treatment of individuals with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Source: FDA website
New Indication 07-11-17
Zypitamag
The Food and Drug Administration (FDA) approved Zypitamag™ (pitavastatin tablets) for the treatment of primary or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Source: FDA website
New Drug 07-18-17
Nerlynx
The Food and Drug Administration (FDA) approved Nerlynx™ (neratinib tablets) for the extended adjuvant treatment of adults with early stage HER2-overexpressed/amplified breast cancer, to follow trastuzumab-based therapy. Source: FDA website
New Drug 07-17-17
Vosevi
The Food and Drug Administration (FDA) approved Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir tablets) for the retreatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 without cirrhosis or with mild cirrhosis who were previously treated with an NS5A inhibitor-containing regimen or in adults with genotype 1a or 3 who were previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor. Source: FDA website
New Drug 07-18-17
Tremfya
The Food and Drug Administration (FDA) approved Tremfya™ (guselkumab injection) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Source: FDA website
New Drug 07-13-17